Ildong Holdings Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 13, 2022 at 11:54 pm EST
Share
Ildong Holdings Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 4,305.33 million compared to KRW 3,649.95 million a year ago. Net loss was KRW 11,863.12 million compared to KRW 6,369.58 million a year ago. Basic loss per share from continuing operations was KRW 1,051 compared to KRW 564 a year ago. Basic loss per share was KRW 1,051 compared to KRW 564 a year ago.
For the nine months, sales was KRW 14,825.04 million compared to KRW 7,631.27 million a year ago. Net loss was KRW 54,924.12 million compared to KRW 20,667.54 million a year ago. Basic loss per share from continuing operations was KRW 4,864 compared to KRW 1,830 a year ago. Basic loss per share was KRW 4,864 compared to KRW 1,830 a year ago.
Ildong Holdings Co., Ltd., formerly Ildong Pharmaceuticals Co., Ltd., is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products mainly include general drugs and specialty drugs, such as vitamin supplements, digestive medications, vascular medications, probiotics, topical applications, anti-histamines, antipyretics, analgesics, respiratory medications, endocrine medications, psychoneurological medications, dermatological medications, urologic medications, antibiotics and others. It also provides raw materials, such as synthesises, probiotics and others. In addition, through its subsidiaries, it engages in the advertising agency, medical equipment distribution, software development, food processing and other businesses.
ILDONG HOLDINGS CO., LTD. 